Literature DB >> 30213289

MiR-637 suppresses melanoma progression through directly targeting P-REX2a and inhibiting PTEN/AKT signaling pathway.

Jian Zhang1, Wen-Li Liu1, Lu Zhang2, Rui Ge1, Fang He3, Tian-Yuan Gao1, Qiong Tian1, Xin Mu1, Li-Hong Chen1, Wei Chen3, Xu Li3.   

Abstract

MicroRNAs (miRNAs) play important roles in melanoma. Although miR-637 has been suggested to be a tumor suppressor in several cancers, its function in melanoma and the molecular mechanism behind that function remain unclear. In this study, we investigated the role of miR-637 in human melanoma and explored its relevant mechanisms. We found that the expression of miR-637 is significantly downregulated in melanoma tissues and cell lines. While overexpression of miR-637 inhibited melanoma cell proliferation and cell cycle G1-S transition, and induced apoptosis. Inhibition of miR-637 promoted cell proliferation and G1-S transition, and suppressed apoptosis. Subsequent investigation revealed that miR-637 expression was inversely correlated with P-REX2a expression in melanoma tissues. P-REX2a was determined to be a direct target of miR-637 by using a luciferase reporter assay. Overexpression of miR-637 decreased P-REX2a expression at both the mRNA and protein levels, and suppression of miR-637 increased P-REX2a expression. Importantly, silencing P-REX2a recapitulated the cellular and molecular effects seen upon miR-637 overexpression, whereas, overexpression of P-REX2a eliminated the effects of miR-637 overexpression on melanoma cells. Furthermore, both enforced expression of miR-637 or silencing of P-REX2a resulted in activation of PTEN, leading to a decline in AKT phosphorylation. Taken together, our study demonstrates that miR-637 inhibites melanoma cell proliferation by activation of AKT signaling pathway and induces apoptosis through regulation of Bcl-2/Bax expression via targeting P-REX2a. These findings suggest that miR-637 plays a crucial role in melanoma progression, and may serve as a potential novel target for melanoma therapy.

Entities:  

Keywords:  Apoptosis.; Melanoma; P-REX2a; Proliferation; miR-637

Mesh:

Substances:

Year:  2018        PMID: 30213289

Source DB:  PubMed          Journal:  Cell Mol Biol (Noisy-le-grand)        ISSN: 0145-5680            Impact factor:   1.770


  7 in total

Review 1.  MicroRNA Signature in Melanoma: Biomarkers and Therapeutic Targets.

Authors:  Soudeh Ghafouri-Fard; Mahdi Gholipour; Mohammad Taheri
Journal:  Front Oncol       Date:  2021-04-22       Impact factor: 6.244

2.  CircRNA HIPK3 promotes the progression of oral squamous cell carcinoma through upregulation of the NUPR1/PI3K/AKT pathway by sponging miR-637.

Authors:  Weipeng Jiang; Chunxiao Zhang; Xiaoming Zhang; Legang Sun; Jikui Li; Jinhua Zuo
Journal:  Ann Transl Med       Date:  2021-05

3.  MicroRNA-561 Affects Proliferation and Cell Cycle Transition Through PTEN/AKT Signaling Pathway by Targeting P-REX2a in NSCLC.

Authors:  ZiJun Liao; Qi Zheng; Ting Wei; YanBing Zhang; JieQun Ma; Zheng Zhao; HaiFeng Sun; KeJun Nan
Journal:  Oncol Res       Date:  2019-11-11       Impact factor: 5.574

4.  microRNA-637 promotes apoptosis and suppresses proliferation and autophagy in multiple myeloma cell lines via NUPR1.

Authors:  Xuanxin Chen; Anmao Li; Qian Zhan; Zizi Jing; Yiyu Chen; Jianbin Chen
Journal:  FEBS Open Bio       Date:  2020-12-30       Impact factor: 2.792

5.  Dysregulation of miR-637 serves as a diagnostic biomarker in patients with carotid artery stenosis and predicts the occurrence of the cerebral ischemic event.

Authors:  Ting Zhang; Ruijie Liu
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

6.  Circular RNA circ_UBAP2 facilitates the progression of osteosarcoma by regulating microRNA miR-637/high-mobility group box (HMGB) 2 axis.

Authors:  Weiguo Ma; Xin Zhao; Yun Gao; Xiaobin Yao; Junhua Zhang; Qingxia Xu
Journal:  Bioengineered       Date:  2022-02       Impact factor: 3.269

7.  CircRNA EPHB4 modulates stem properties and proliferation of gliomas via sponging miR-637 and up-regulating SOX10.

Authors:  Chen Jin; Jie Zhao; Zhi-Ping Zhang; Ming Wu; Jian Li; Bo Liu; Xin- Bin Liao; Yu-Xiang Liao; Jing-Ping Liu
Journal:  Mol Oncol       Date:  2020-12-16       Impact factor: 7.449

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.